Lv31
390 积分 2023-07-11 加入
The fate of sotorasib: a regulatory failure potentially harming patients
5个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
6个月前
已完结
Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring
11个月前
已完结
FDA experiences with a centralized statistical monitoring tool
11个月前
已完结
Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs
11个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
11个月前
已完结
Phase III Evaluation of Treatment Combinations in Three-Arm Trials
1年前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
2年前
已完结
皖公网安备34019202002308
